|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **S. No.** | **Delivery System** | **Drug** | **Brand Name/ Patent/ Clinical trial** | **Mode of Action/ Disease** | **Summary** | **Year of approval/ Application / study** | **Company/ Patent Number/ Clinical trial status** |
|  | SNEDDS | Saquinavir | Fortovase® | HIV/AIDS | Soft gelatin capsules containing SNEDDS of saquinavir have shown 3 times increase in bioavailability in comparison to Invirase | 1997 | Hoffman La Roche |
|  | SNEDDS | Ritonavir | Norvir® | HIV/AIDS | Drug from SNEDDS had shown higher bioavailability in fed state then in fasted state | 1998 | Abbott Laboratories |
|  | Nanoemulsion | Rifamixin | Patent | Antibacterial/Antifungal | Oil-in-water nanoemulsion containing rifamixin was prepared to enhance the stability of drug, containing 12 parts of oil, 35 parts of surfactant, 7 parts of co-surfactant and 43 parts of water showed globule size of 10-100 nm | 2017 | CN107550861 |
|  | Nanoemulsion | Moxifloxacin | Patent | Antibacterial | Enhanced stability of moxifloxacin | 2018 | CN 107550858 |
|  | Nanoemulgel | Terbinafine HCl | Patent | Antifungal | Enhanced permeability through the skin with increase in retention time of drug on skin; able to reduce the infection in 12 days | 2014 | 2106/CHE/2014 |
|  | Nanoemulsion | Clobetasol propionate | Clinical trial | Cataract | Oil-in-water, clear nanoemulsion containing clobetasol propionate was compared with placebo in the treatment of inflammation and pain associated with cataract surgery administered as one drop four times a day for fourteen days | 2020 | Phase 3 |
|  | Nanoemulsion | Brimonidine tartrate | Clinical trial | Dry eye | Nanoemulsion eye drop solution containing brimonidine tartrate 0.2% was compared with placebo to evaluate the effect on production of tears in treatment of dry eye disease | 2018 | Phase 3 |
|  | SNEDDS | Voriconazole | Clinical trial | Tinea Versicolor | Self- nanoemulsifying intermediate gel containing voriconazole was evaluated in treatment of tinea versicolor by topical application for once in a day and twice a day in comparison to placebo | 2018 | Phase 2 |
|  | SNEDDS | Itraconazole | Clinical trial | Tinea Versicolor | Self- nanoemulsifying intermediate gel containing itraconazole is evaluated in treatment of tinea versicolor by topical application for once in a day and twice a day in comparison to placebo | 2018 | Phase 2 |

**Table S1:** Nanoemulsions/modified-nanoemulsion based containing antimicrobial agent (i) marketed and patented products; (ii) products in clinical trials [98–100]

SNEDDS: Self-nanoemulsifying drug delivery system; HIV: Human immunodeficiency virus; AIDS: Acquired immunodeficiency syndrome